lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wrong as usual. Bullshit, bullshit, bullshit.
Approval this year.
Wrong, wrong, wrong.
DCVax approval by Q4 2023.
In fact management delivers results no matter what curve balls are thrown in their direction. The multi billion dollar court settlement paid out by spoofing market makers will be the perfect example.
DCVax approval by Q4 2023.
They don't know when it will be finished.
They're not going to give selective disclosure to an individual shareholder as this would be RegFD (insider training) violation.
Northwest Biotherapeutics has no competition. Moreover with first mover advantage they can buy out any competing technologies. In this way they have the potential to become the next BP firm.
After we uplist I expect they will buy more shares. Institutional investors are placing bets with other people's money. They don't like to watch their returns destroyed by illegal spoofing, wash trading, and who knows what other manipulation we are now facing on OTC.
The fact that they own our shares means they know a lot about us. The fund manager possibly spoke to Les Goldman. Given they have a billion AUM I don't know how anyone could dismiss this very significant progress!
1B AUM fund!
I will be adding more next week. Added 65K shares this week.
Thank you dstock for posting this tonight!
1B AUM. Mutual funds are not some swing traders algo. They have serious due diligence. We will see their position increase.
Billion dollar John Hancock mutual fund loves NWBO!
That's a John Hancock mutual fund!
Risk averse institutional investors are buying NWBO!
Nearly all companies disclose new drug applications, though there's no FDA rule that makes this mandatory. I can see why they could elect to not make this announcement given the criminal manipulation of our share price. As we all know, even the best news brings retracement in our stock price.
Filing for approval does not determine the outcome of an application. The submission of an application for that reason isn't material as a reasonable person cannot ascertain what regulators will do with the application. In addition, as you know, our SEC filings have a risk section which points out that our novel design may lead to rejection by regulators. For this reason, even being a single product company, I believe managment have legal cover to not announce submission or acceptance if they believed this would be part of their fiduciary duty.
The SEC has argued successfully in multiple lawsuits that negative feedback from regulators must be communicated promptly and accurately. Such feedback includes regulators asking for another trial. MHRA already invalidated that possibility by approving the post-appoval PIP. Therefore, I do not personally believe we will hear anything until MHRA approves DCVax. The opposite may have been said in the past to shareholders on this forum though I haven't seen that listed among our firm's standard operating procedures for communicating regulatory matters.
I expect our management team to pivot when required, especially if the outcome would be in the best interest of shareholders via facilitating a massive short squeeze. We need that for a immediate uplisting which will greatly help stabilize our share price! I personally believe this will be the outcome. You are free to disagree.
Management are under no legal obligation to disclose the submission of an application for approval nor that it has been accepted and under review. Drug regulators do not ever discuss an application under consideration.
It's logical to infer that management are in a rolling review process as every jurisdiction has one in place. The coauthor of NAFTA and EU Patent Law, who worked for the HW Bush Administration, graduated from Harvard, taught at Georgetown, and has a slew of accomplishments, would not likely take the most inefficient path to approval. Leaving the application on a shelf while the entirety gets completed makes zero sense when they can be submitted in modules.
Given the conspiracy to destroy this company they may simply wait until approval. In my personal opinion I think we will wake up one day to learn of MHRA approval without any prior notification. This will provide the maximum impact facilitating an uplist to NYSE or Nasdaq.
Gary, there's no doubt that DCVax will be approved while I am sure it's being discussed being the only efficacious treatment for GBM featured in the most read JAMA article. It's simply depressing to see the inept forum yesterday. I am very thankful to not be a GBM patient as if I was I would probably lose a lot of hope watching this nihilistic sham. I think you would agree that attending a conference like ASCO leaves the impression of at least innovation in process.
Sadly today though my takeaway from yesterday was stagnation which we all know isn't the reality for oncology research! Hopefully FDA beats MHRA to approve this taxpayer-funded treatment before Q4! America has a solid record of achieving amazing goals but I didn't get the impression that we have the best leadership in place at least at this glad-handing forum. Hopefully soon innovators can take forefront of the narrative as we know there's a great message coming out of UCLA with murcidencel.
Statistics are an undergraduate course. The issue isn't educational background but cognitive biases.
2.5B in the federal budget happens to be chump change. This event was supposed to be about helping Glioblastoma patients. If they wanted to simply announce new funding well every research institution has a grants office keenly aware of funding mechanisms available from the federal government.
Send out a press release instead of gathering stakeholders then spreading misinformation like there's been no research advances made for Glioblastoma!
False!
The NCI Director insulted both Roger Stupp and Linda Liau, two decades of research by hundreds of people who participated in their respective labs over that time, by stating that therapies do not cross the blood brain barrier.
This forum was a complete joke!
Northwest management do not own a majority of the shares hence why a hostile takeover could be an issue. Yet you're claiming they run this company like a dictatorship? Lots of contradictory statements without evidence per usual.
If there's concerns about promoting an unapproved drug then don't have the forum until DCVax has FDA approval. This was a useless event with no meaningful benefit for patients. Very tone deaf. People are dieing while the head of NCI says untruths like no treatments pass the blood brain barrier. This is the buffoon who controls the purse strings. Our tax dollars.
These are competitive grants awarded to projects with merit. Academia is filled with junk science endeavors while Linda Liau has risen to the top. It would made sense for her to get a mention in the context of the millions going to UCLA, JAMA, etc. Instead we had completely wrong statements like treatments don't cross the blood brain barrier.
JAMA loves DCVax.
No, uncle sam does not fund biotechnology companies directly. They fund universities, using competitive grants, which partner with those corporations. Eg UCLA, NIH, SPORE, and ATL-DC (murcidencel).
It would be very inappropriate if government picked the winners and losers directly. We learned today they're wholly incompetent in that regard so thankfully a system of competitive grants exists to ensure the best science, eventually, rises to the forefront.
No doubt we will have more validation of DCVax very soon.
The NCI Director did a piss poor job of representing an organization that helped fund murcidencel through the SPORE program at UCLA. He also said nothing gets past the blood brain barrier. So basically we went back in time two decades at this forum. Sounds like progress.
The Cancer Moonshot forum had nothing to do with NWBO.
None of the speakers will be evaluating the NWBO BLA.
I bought more shares after the event was over as our fundamentals are in no way undermined by this fundraising event.
Even stupid people need a job.
They were hard at work today with their hands out for that government cheese.
Added more shares today.
Of course the NCI Director can mention the generic name ATL-DC which UCLA uses in their government-funded trials. They fund SPORE at UCLA, FFS!
But he seems to be an idiot unaware of even TMZ. Thankfully he won't be reviewing the DCVax BLA.
Attending this farcical forum has absolutely no bearing on DCVax approval. This was simply an opportunity for groups to raise more money.
She probably declined the invitation.
I don't want Linda Powers getting in this clown car.
Yes, they're all morons.
DCVax is government sponsored!
It's a ridiculous forum that's for sure.
I agree I can't believe we heard that GBM treatments do not cross the blood brain barrier.
Some bureaucrats like to gather in order to justify their salaries. This clearly isn't any meaningful forum so I am glad management didn't waste their time at this farcical distraction.
Trillion-dollar technology!
I believe you are 100% correct, sir.
Do you mean the prior history of erroneous lawsuits against the company being thrown out of federal court, shady failed PhD candidates working for short sellers bragging about nearly bankrupting the company, as well as yellow journalism being leveraged against this life-saving technology?
All of these efforts against NWBO cost us many millions of dollars.
The shady tactics are all coming from one direction in an effort to undermine the coauthor of NAFTA and EU Patent Law who happens to be a woman with a cure for cancer!
Based upon known facts it's highly probable that management are engaged in rolling review with the FDA and MHRA. From the 2022 ASM we learned that the application was in process for the entirety of that year. It makes little sense the documents would sit on a shelf when they can be submitted in a modular fashion.
The SEC would not require this be disclosed, as it's not material until the regulators sign off on approval or issue a denial, whereas regulatory approval processes are private meaning drug regulators themsleves do not disclose any applications.
The firm remains in a quiet period while nothing has leaked partially because of this wise decision to not be verbose at this crucial time. RegFD violation, more erroneous lawsuits or complaints, would be very bad hence why management engage in the best practice of remaining quiet until approval.
No evidence exists contrary to my claims on this matter.
I believe we will have MHRA approval this year. If management thought it would be next year then they wouldn't be sending their millions of shares to GRATs which cost many tens of thousands to setup in attorney and accountant fees. In my personal opinion that makes a whole lot of sense to do before a massive appreciation in share value. It's ideal to do it when the share price remains low.
Remember that GRATs are specifically designed to transfer the appreciation from the assets in the GRAT during the term. For that reason, it is best to fund GRATs with assets that are expected to experience significant growth during the GRAT term, either through market movements for publicly traded assets or through a liquidity event for privately held investments.
Northwest Biotherapeutics in my opinion are very close to approval. We need to stay focused and not get distracted.